Medivation (MDVN) Shares are Down -1.16%

Medivation (MDVN) has risen sharply, recording gains of 1.85% in the past 4 weeks. However, the stock has corrected -1.16% in the past 1 week, providing a good buying opportunity on dips. Medivation (MDVN) : During the past 4 weeks, traders have been relatively bearish on Medivation (MDVN), hence the stock is down -0.62% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.58% relative to the S&P 500.

Medivation (NASDAQ:MDVN): The stock opened at $63.76 on Friday but the bulls could not build on the opening and the stock topped out at $64.09 for the day. The stock traded down to $62.95 during the day, due to lack of any buying support eventually closed down at $63.25 with a loss of -0.75% for the day. The stock had closed at $63.73 on the previous day. The total traded volume was 1,426,801 shares.

The stock has recorded a 20-day Moving Average of 0.99% and the 50-Day Moving Average is 3.61%. Medivation, Inc. is up 5.42% in the last 3-month period. Year-to-Date the stock performance stands at 30.84%.

Medivation (MDVN) : Currently there are 14 street experts covering Medivation (MDVN) stock. The most bullish and bearish price target for the stock is $76 and $40 respectively for the short term. The average price target of all the analysts comes to $63.5. The estimated standard deviation from the target is $10.04.


Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *